Profile data is unavailable for this security.
About the company
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
- Revenue in USD (TTM)111.55m
- Net income in USD-311.58m
- Incorporated2005
- Employees270.00
- LocationSyndax Pharmaceuticals Inc730 Third Avenue, 9Th FloorNEW YORK 10017United StatesUSA
- Phone+1 (781) 419-1400
- Fax+1 (781) 419-1420
- Websitehttps://syndax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.41 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.68bn | 48.00 | -- | 5.20 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.69bn | 580.00 | -- | -- | -- | 2.81 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Ardelyx Inc | 398.23m | -56.55m | 1.70bn | 395.00 | -- | 11.04 | -- | 4.28 | -0.2364 | -0.2364 | 1.66 | 0.635 | 0.9326 | 2.57 | 6.14 | 1,008,187.00 | -13.24 | -35.80 | -16.15 | -45.22 | 88.21 | 86.06 | -14.20 | -80.49 | 4.11 | -2.07 | 0.5671 | -- | 168.06 | 129.14 | 40.76 | -- | 25.48 | -- |
| Pharvaris NV | 0.00 | -194.32m | 1.70bn | 108.00 | -- | 4.66 | -- | -- | -3.46 | -3.46 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.71bn | 155.00 | -- | 8.83 | -- | 25.64 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.71bn | 43.00 | -- | 4.38 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| MannKind Corp | 313.79m | 28.76m | 1.73bn | 407.00 | 60.79 | -- | 46.51 | 5.51 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.73bn | 263.00 | -- | 5.48 | -- | 12.89 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.81bn | 5.00 | -- | 5.98 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.82bn | 128.00 | 48.32 | 5.71 | 42.90 | 8.86 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Syndax Pharmaceuticals Inc | 111.55m | -311.58m | 1.84bn | 270.00 | -- | 15.92 | -- | 16.47 | -3.61 | -3.61 | 1.29 | 1.33 | 0.2282 | -- | 4.67 | 413,151.80 | -63.74 | -32.19 | -77.50 | -35.11 | 95.44 | -- | -279.31 | -440.06 | 4.42 | -87.92 | 0.7487 | -- | -- | 73.25 | -52.25 | -- | -- | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 43.69m | -715.54m | 1.86bn | 840.00 | -- | 1.68 | -- | 42.60 | -1.81 | -1.81 | 0.109 | 2.13 | 0.0411 | -- | 3.62 | 52,010.71 | -67.31 | -42.93 | -76.86 | -48.71 | -59.01 | -- | -1,637.81 | -828.92 | -- | -- | 0.0195 | -- | 32.00 | 90.93 | -41.33 | -- | 28.49 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.87bn | 122.00 | -- | 5.30 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.99bn | 291.00 | -- | 6.09 | -- | 74.21 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
Data as of Feb 13 2026. Currency figures normalised to Syndax Pharmaceuticals Inc's reporting currency: US Dollar USD
52.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 30 Sep 2025 | 8.52m | 9.80% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.77m | 7.79% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.53m | 6.36% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 4.84m | 5.57% |
| Point72 Asset Management LPas of 30 Sep 2025 | 4.32m | 4.97% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.85m | 4.43% |
| Eversept Partners LPas of 30 Sep 2025 | 3.47m | 3.99% |
| Adage Capital Management LPas of 30 Sep 2025 | 3.31m | 3.81% |
| Kingdon Capital Management LLCas of 30 Sep 2025 | 2.50m | 2.88% |
| Franklin Advisers, Inc.as of 30 Sep 2025 | 2.39m | 2.75% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
